Clinical and Immunological Effects of Recombinant Interleukin 2 Given by Repetitive Weekly Cycles to Patients with Cancer

Keyphrases

• Interleukin-2 100%
• Patients with Cancer 100%
• Clinical Effect 100%
• Weekly Cycle 100%
• Immunological Effects 100%
• Recombinant interleukin-2 100%
• Lymphocytosis 66%
• Daudi 66%
• Anemia 33%
• Natural Killer Cells 33%
• Life-threatening 33%
• Anti-tumor Response 33%
• Dose Level 33%
• Drug-resistant Tumor 33%
• Lymphocytes 33%
• Renal Cell Carcinoma 33%
• Liver Function 33%
• Tumor Cell Lines 33%
• Fever 33%
• Absolute Count 33%
• Continuous Infusion 33%
• Eosinophilia 33%
• Cytotoxic Activity 33%
• Two-dose 33%
• Immunological Changes 33%
• Patients Included 33%
• Hepatic Metastasis 33%
• Second Course 33%
• Lymphocyte Count 33%
• Pulmonary Metastasis 33%
• Circulating Lymphocytes 33%
• In Vivo Antitumor Activity 33%
• Direct Lysis 33%

Medicine and Dentistry

• Recombinant Interleukin 2 100%
• Interleukin 2 100%
• Lymphocyte 100%
• In Vitro 66%
• Lymphocytosis 66%
• Side Effect 33%
• Lung Metastasis 33%
• Liver Metastasis 33%
• Anemia 33%
• Liver Function 33%
• Eosinophilia 33%
• Rigor 33%
• Continuous Infusion 33%
• Tumor Cell Line 33%
• Kidney Carcinoma 33%
• Immunotherapy 33%
• Natural Killer Cell 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Recombinant Interleukin 2 100%
• Interleukin 2 100%
• Lymphocytosis 66%
• Side Effect 33%
• Liver Metastasis 33%
• Rigor 33%
• Lung Metastasis 33%
• Kidney Carcinoma 33%
• Immunotherapy 33%
• Neoplasm 33%
• Anemia 33%
• Eosinophilia 33%